The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

Press Releases Subscribe to our News

13. Mai 2022

Regulatory

Biosergen successfully completes first cohort of BSG005 phase I trial

Release
02. Mai 2022

Non-Regulatory

Biosergen is preparing a Phase II study of BSG005 against Mucormycosis, the Black Fungus.

Release
19. April 2022

Non-Regulatory

The first subjects dosed successfully with no adverse events in the phase I trial of BSG005

Release
07. April 2022

Regulatory

The first subject has been dosed in the phase I trial of BSG005

Release
31. März 2022

Regulatory

Biosergen publishes interim report for fourth quarter 2021

Biosergen Q4 financial report press release
Q4-2021 Financial Report
30. November 2021

Regulatory

Biosergen publishes interim report for the third quarter 2021

Q3-2021 Financial Report
Biosergen Q3 financial report press release
31. August 2021

Regulatory

Biosergen publishes interim report for the second quarter 2021

Q2-2021 Financial Report
Biosergen Q2 report press release
24. August 2021

Non-Regulatory

Biosergen’s application to start human clinical trials with BSG005 is approved

Release
19. August 2021

Non-Regulatory

Tine Kold Olesen will join Biosergen AB as Chief Operating Officer

Release
27. Juni 2021

Regulatory

Biosergen’s groundbreaking antifugal drug BSG005 is granted Orphan Drug status in the United States

Release
23. Juni 2021

Non-Regulatory

BIOSERGEN HAS BEEN APPROVED FOR LISTING ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM.

Biosergen listing approval
08. Juni 2021

Regulatory

BIOSERGEN’S OFFERING IS FULLY SUBSCRIBED

Biosergens offering fully subscribed
31. Mai 2021

Non-Regulatory

The outbreak of mucormycosis (the so-called “Black Fungus”) in India is a prime example of the great need for a safer antifungal drug with true fungicidal activity

Release
19. Mai 2021

Non-Regulatory

BIOSERGEN INTENDS TO LIST ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM

BIOSERGEN INTENDS TO LIST ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM (PDF)

Non-Regulatory

BIOSERGEN AVSER ATT NOTERA SINA AKTIER PÅ NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM

BIOSERGEN AVSER ATT NOTERA SINA AKTIER PÅ NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM (PDF)